Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lymphoma 3Leukemia, Myeloid, Acute 3Lymphoma, B-Cell 2Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Neuroblastoma 1Myelodysplastic Syndromes 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Temozolomide 7Vincristine 5X-Rays 4Specimen Handling 4Phantoms, Imaging 4Magnetic Resonance Spectroscopy 4Irinotecan 4Cyclophosphamide 4cabozantinib 3Ifosfamide 3Etoposide 3Doxorubicin 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2liposomal doxorubicin 2ivosidenib 2Topotecan 2Radiation 2Nuclear Medicine Department, Hospital 2LY3023414 2Eflornithine 2Congresses as Topic 2trifluridine tipiracil drug combination 1talazoparib 1silmitasertib 1romiplostim 1regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Ewing × etoposide phosphate × 90 days × Clear all
NCT02306161 2026-06-03

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
312 enrolled 14 charts
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡